Trials / Completed
CompletedNCT02216214
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 888 (actual)
- Sponsor
- Astellas Pharma Global Development, Inc. · Industry
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to assess the efficacy, safety and tolerability of mirabegron versus placebo in the treatment of older adult subjects with OAB.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mirabegron | oral tablet |
| DRUG | Placebo | oral tablet |
Timeline
- Start date
- 2014-10-07
- Primary completion
- 2017-11-29
- Completion
- 2018-01-02
- First posted
- 2014-08-13
- Last updated
- 2024-11-22
- Results posted
- 2019-02-15
Locations
120 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02216214. Inclusion in this directory is not an endorsement.